Abstract:Background: High incidence of gastric cancer (GC), its aggressive clinical course, rapid tumor dissemination, low sensitivity to chemotherapy and lack of reliable laboratory diagnostic criteria urgently require a search for the most informative markers associated with key biologic properties of the tumors. Aim: Comparative analysis of galectin-3, matrix metalloproteinase (MMP)-2, and MMP-9 levels in peripheral blood of GC patients and healthy donors, assessment of association of these markers with clinical morphological characteristics of the disease, and prognosis of overall and relapse-free survival. Materials and methods: Sixty (60) primary treatment-nave GC patients (38 men, 22 women) aged 29 to 81 years and 90 healthy donors compatible with their age and sex were included into the study. Galectin-3 was measured in EDTA plasma, MMP-2 and MMP-9 in serum with standard direct enzyme immunoassay kits "Human MMP-2 (total)", "Human MMP-9 (total)", "Human Galectin-3" (RD Systems, USA). Results: Plasma galectin-3 concentration in the GC patients was significantly higher than in the healthy controls (median 12.9 and 10.6 ng/ml, respectively; p 0.0001). No difference in serum MMP-9 levels between GC patients and control subjects were found, while MMP-2 level in the control group was significantly higher, than in the GC patients (p = 0.039). No association between galectin-3, MMP-2, and MMP-9 blood levels in the GC patients could be identified. In contrast to GC patients, there was a positive correlation of plasma galectin-3 with age in the control group (rs = 0.51, p 0.005). No associations between the biomarkers levels in blood and clinical and morphological characteristics of GC were established, except MMP-9 being higher at Т4а invasion depth as compared to the earlier Т2 level. Marked differences in the overall survival depending on plasma galectin-3 levels were found, with the cut-off level of 12.9 ng/ml: the 5-year overall survival in the patients with low galectin-3 was better, than in those with its higher level (50 and 43%, respectively; however, the difference was non-significant, р 0.1). Both overall and relapse-free survival of the GC patients was higher in those with low ( 212 ng/ml) serum MMP-2: the 5-year overall survival in this group comprised 60% versus 23% in the patients with higher MMP-2 (p = 0.018). The difference in relapse-free survival was non-significant. Serum MMP-9 levels had no significant impact on the survival of GC patients. Conclusion: The ambiguous data on the clinical role of galectin-3, MMP-2, MMP-9 in GC obtained in this study indicate the necessity of further investigation of their possible utility for the diagnostics and prognosis of treatment results.

Relations Between MMP-2/9 and Type Ⅳ Collagen and Aromatic Amino Acids Levels in Gastric Juice in Gastric Cancer Patients

Expressions of MMP-1,MMP-8 and MMP-13 in gingival tissue of patients with aggressive periodontitis

Expression of Matrix Metalloproteinase-9 and Their Correlation with Tumor Invasion, Metastasis in Gastric Carcinoma

Polypeptide N -acetylgalactosaminyltransferase-6 expression in gastric cancer.

Expressions of MMP-9 and PEDF and Their Correlation with Tumor Invasion and Lymph Node Metastasis in Gastric Carcinoma

Differential Expression of COL6 Family is a Potential Tumor Marker for Predicting Gastric Cancer

Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer

Collagen: a possible prediction mark for gastric cancer.

A potential role of collagens expression in distinguishing between premalignant and malignant lesions in stomach.

Overexpression of Collagen VI Α3 in Gastric Cancer

CLINICAL SIGNIFICANCE OF SERUM HYALURONIC ACID、TYPE III PROCOLLAGEN PEPTIDE、TYPE IV COLLAGEN AND LAMININ IN PATIENTS WITH GASTRIC CANCER

Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients

[The Correlation Between Polymorphisms of Matrix Metalloproteinase-2 and -9 Genes and Colorectal Cancer of Chinese Patients].

Association of Matrix Metalloproteinase‐2 and ‐9 Promoter Polymorphisms with Colorectal Cancer in Chinese

Matrix Metalloproteinase-7 Mrna and Protein Expression in Gastric Carcinoma: a Meta-Analysis

COL12A1, a Novel Potential Prognostic Factor and Therapeutic Target in Gastric Cancer.

Relationship of MMP-2mRNA Expression with Clinical Pathological Features and Prognosis in Gastric Cancer

Interactions between gastric microbiota and metabolites in gastric cancer

Research on Clinical Application Value of MMP Quantitative Array in Diagnosis of Gastric Cancer

The overexpression of COL6A3 has been demonstrated to correlate with high-grade ovarian cancer and contributes to cisplatin resistance; however, its role in human gastric cancer

Analysis Of Collagen Type X Alpha 1 (Col10a1) Expression And Prognostic Significance In Gastric Cancer Based On Bioinformatics